Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase

Journal of the National Cancer Institute

Volumn 90, Issue 21, 1998, Pages 1621-1625

  Warrell Jr , Raymond P ^a,b   He, Li Zhen ^a   Richon, Victoria ^a   Calleja, Elizabeth ^a   Pandolfi, Pier Paolo ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CASE REPORT; DRUG ACETYLATION; FEMALE; HUMAN; PRIORITY JOURNAL; TARGET CELL; TRANSCRIPTION REGULATION;

EID: 3643104150     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.21.1621     Document Type: Article

References (40)

1. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52.
2. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to DNA. Cell 1993;72:73-84.
3. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/CBO-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996;382:319-24.
4. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996;87:953-9.
5. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996;384:641-3.
6. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998;391:811-4.
7. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 1998;391:815-8.
8. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat Genet 1998;18:126-35.
9. Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978;14:105-13.
10. Dover GJ, Brusilow S, Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med 1992;327:569-70.
11. Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996;335:855-9.
12. Miller WH Jr, Levine K, DeBlasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA. Blood 1993;82:1689-94.
13. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 1998;95:3003-7.
14. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990;347:558-61.
15. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-2.
16. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia: I. Clinical results. Blood 1990;76:1704-9.
17. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 1991;324:1385-93.
18. Warrell RP Jr, de The H, Wang ZY, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993;329:177-89.
19. Wolffe AP, Pruss D. Targeting chromatin disruption: transcription regulators that acetylate histones. Cell 1996;84:817-9.
20. Ptashne M, Gann A. Transcriptional activation by recruitment. Nature 1997;386:569-76.
21. Horlein AJ, Naar AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995;377:397-404.
22. Kurokawa R, Soderstrom M, Horlein A, Halachmi S, Brown M, Rosenfeld MG, et al. Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 1995;377:451-4.
23. Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995;377:454-7.
24. Alland L, Muhle R, Hou H Jr, Potes J, Chin L, Schreiber-Agus N, et al. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 1997;387:49-55.
25. Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, Torchia J, et al. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 1997;387:43-8.
26. Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, et al. The translocation t(8;16) (p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996; 14:33-41.
27. Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, et al. MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16) (q23;p13.3). Proc Natl Acad Sci U S A 1997;94:8732-7.
28. Dhordain P, Albagli O, Lin RJ, Ansieau S, Quief S, Leutz A, et al. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci U S A 1997;94:10762-7.
29. Ayer DE, Lawrence QA, Eisenman RN. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast represser Sin3. Cell 1995;80:767-76.
30. Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Buida P, et al. An amino-terminal domain of Mxil mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 1995;80:777-86.
31. Laherty CD, Yang WM, Sun JM, Davie JR, Seto E, Eisenman RN. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell 1997;89:349-56.
32. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-9.
33. Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, et al. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 1994;54:1690-4.
34. Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 1992;80:2604-9.
35. Jurcic JG, Miller WH, BeBlasio A, Scheinberg DA, Warrell RP Jr. Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemia [abstract]. Blood 1996;88(Suppl):635a.
36. Gore SD, Miller CB, Weng LJ, Burks K, Griffin CA, Chen TL, et al. Improved hematopoiesis in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) following administration of the putative differentiating agent sodium phenylbutyrate (SPB) [abstract]. Blood (Suppl) 1996;88:582a.
37. Carducci M, Bowling M, Eisenberger M, Sinibaldi V, Chen TL, Buckley N, et al. Oral sodium phenylbutyrate (PB) for refractory solid tumors: phase 1 and bioavailability assessment [abstract]. Proc ASCO 1998;17:215a.
38. Ferrari AC, Waxman S. Differentiation agents in cancer therapy. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer chemotherapy and biological response modifiers. Annual 15. New York: Elsevier Science; 1994. p. 337-66.
39. Weng LJ, Yu K, FU S, Gore SD. Synergy between retinoic acid (RA) and the putative differentiating agent sodium phenylbutyrate (SPB) promotes maximal cytostasis and differentiation of myeloid cells at clinically achievable doses of SPB [abstract]. Blood (Suppl) 1996;90:329a.
40. Sidell N, Chang B, Yamashiro JM, Wada RK. Transcriptional upregulation of retinoic acid receptor β (RARβ) expression by phenylacetate in human neuroblastoma cells. Exp Cell Res 1998;239:169-74.